Clinical Trials Browser

Withdrawn × 130-nm albumin-bound paclitaxel × Clear all

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT06592664 2025-06-06

FORTIFIDE

Phase 1/2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03169790 2025-02-24

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase 1/2 Withdrawn

Lymphoma, Non-Hodgkin

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Melanoma

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

Neoplasm Metastasis

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT05233696 2022-12-06

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04754815 2022-03-29

HFHS 21-01

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02662634 2022-03-18

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02300935 2019-05-30

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Phase 1 Withdrawn

Melanoma, Neoplasm Metastasis

NCT03392571 2019-05-07

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Phase 2 Withdrawn

Gastrointestinal

Resectable Pancreatic Cancer

NCT02405910 2017-11-06

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02718742 2016-04-18

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Phase 2 Withdrawn

Recurrent Bladder Urothelial Carcinoma

NCT02033538 2015-03-05

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus

Phase 2 Withdrawn

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02048943 2015-01-09

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT01933061 2014-02-04

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Phase 2 Withdrawn

Melanoma